Ten months after devastating failure, Roche says it sees path forward for Huntington’s drug
If you had to pick 2021’s biggest drug development disappointment, it’d be hard to overlook the Roche-Ionis Huntington’s disease trial.
The Phase III study represented the community’s first major hope of having a treatment for the underlying cause of a devastating disease that steals most patients’ cognition in mid-life. Then, in March, Roche had to cut the trial short because the drug seemed to somehow be making patients worse.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.